一个系统的在线生活证据对阿尔茨海默病实验研究的总结
Kaitlyn Hair1, Emma Wilson1, Olena Maksym1
1Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.
Journal of neuroscience methods
|July 4, 2024
概括
阿尔茨海默病的研究面临的挑战是证据合成. AD-SOLES是一个新的自动化工具,可以收集,整理和可视化体内实验数据,加速系统审查和提高研究质量.
科学领域:
- 神经科学是一个神经科学.
- 生物医学研究生物医学研究
- 数据科学数据科学数据科学
背景情况:
- 阿尔茨海默病 (AD) 治疗的发展受到基础研究质量和可重复性的问题所阻碍.
- 证据生成的快速步伐使得传统的系统审查具有挑战性.
- 确保临床前AD研究的严谨性和透明度对于治疗转化至关重要.
研究的目的:
- 开发一种自动化工作流程,用于收集,策划和可视化来自阿尔茨海默病研究中的体内实验证据.
- 面对快速增长的科学文献,解决证据综合和评估的挑战.
- 提高临床前AD研究数据的质量,可复制性和可访问性.
主要方法:
- 开发AD-SOLES,这是一个自动化工具的集成工作流.
- 实施自动选和文本挖掘方法,从出版物中提取数据.
- 创建一个公开可访问的交互式仪表板,用于数据可视化和查询.
主要成果:
- AD-SOLES提供了一个公开可访问的仪表板,总结了体内实验中的最新证据.
- 该系统跟踪报告质量和透明度,使用户能够有效地找到相关研究.
- 与传统方法相比,自动选加快了系统审查的起点.
结论:
- AD-SOLES自动化了证据的收集,策划和可视化,解决了快速数据生成的挑战.
- 该工具旨在指导研究改进,减少浪费,识别知识差距,并支持知情决策.
- 通过提高证据的可访问性和评估,AD-SOLES可以促进更好的研究成果,并加速开发有效的阿尔茨海默病治疗方法.
更多相关视频
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.7K
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.2K
相关概念视频
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177
